Whitehawk Therapeutics (WHWK) Stock Price, News & Analysis

Company Overview

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Key Stats

• Today's Range: $4.12 to $4.28
• 50-Day Range: $3.00 to $4.23
• 52-Week Range: $1.53 to $4.48
• Volume: 112,589 shs
• Average Volume: 218,371 shs
• Market Capitalization: $208.10 million
• P/E Ratio: 8.96
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Moderate Buy

Whitehawk Therapeutics Stock Analysis - MarketRank™

Whitehawk Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 9th out of 59 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Whitehawk Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Whitehawk Therapeutics has a consensus price target of $7.00, representing about 66.3% upside from its current price of $4.21.

Amount of Analyst Coverage

Whitehawk Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Whitehawk Therapeutics are expected to decrease in the coming year, from ($1.43) to ($1.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Whitehawk Therapeutics is 8.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.04.

Price to Earnings Ratio vs. Sector

The P/E ratio of Whitehawk Therapeutics is 8.96, which means that it is trading at a less expensive P/E ratio than the Manufacturing sector average P/E ratio of about 23.37.

Price to Book Value per Share Ratio

Whitehawk Therapeutics has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.30% of the float of Whitehawk Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Whitehawk Therapeutics has a short interest ratio ("days to cover") of 3.66, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Whitehawk Therapeutics has recently increased by 12.41%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Whitehawk Therapeutics does not currently pay a dividend.

Dividend Growth

Whitehawk Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.16

News Sentiment

Whitehawk Therapeutics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Whitehawk Therapeutics this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for WHWK on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

1 people have added Whitehawk Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Whitehawk Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,584,564.00 in company stock.

Percentage Held by Insiders

49.90% of the stock of Whitehawk Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.08% of the stock of Whitehawk Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

WHWK Stock Analysis - Frequently Asked Questions

How have WHWK shares performed this year?

Whitehawk Therapeutics' stock was trading at $2.42 at the start of the year. Since then, WHWK stock has increased by 74.0% and is now trading at $4.21.

How were Whitehawk Therapeutics' earnings last quarter?

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) posted its quarterly earnings results on Thursday, March, 12th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.21.

How do I buy shares of Whitehawk Therapeutics?

Shares of WHWK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/12/2026
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:WHWK
• CIK: 1422142
• Web: N/A
• Phone: (424) 473-8055
• Fax: N/A
• Employees: 21
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Whitehawk Therapeutics: $7.00
• High Price Target: $8.00
• Low Price Target: $6.00
• Potential Upside/Downside: +66.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.47
• Trailing P/E Ratio: 8.96
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.60 million
• Net Margins: N/A
• Pretax Margin: -288.26%
• Return on Equity: -62.88%
• Return on Assets: -58.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.26
• Quick Ratio: 10.26

Sales & Book Value

• Annual Sales: $7.14 million
• Price / Sales: 29.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.89 per share
• Price / Book: 1.46

Miscellaneous

• Outstanding Shares: 49,430,000
• Free Float: 24,763,000
• Market Cap: $208.10 million
• Optionable: N/A
• Beta: 0.70